Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Relay Therapeutics (RLAY) Shares Outstanding (2020 - 2025)

Relay Therapeutics (RLAY) has disclosed Shares Outstanding for 6 consecutive years, with $173.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Shares Outstanding rose 3.64% to $173.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $173.9 million, a 3.64% increase, with the full-year FY2025 number at $173.9 million, up 3.64% from a year prior.
  • Shares Outstanding was $173.9 million for Q4 2025 at Relay Therapeutics, up from $172.6 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $173.9 million in Q4 2025 to a low of $90.4 million in Q1 2021.
  • A 5-year average of $131.3 million and a median of $122.6 million in 2023 define the central range for Shares Outstanding.
  • Peak YoY movement for Shares Outstanding: soared 1986.57% in 2021, then grew 1.95% in 2023.
  • Relay Therapeutics' Shares Outstanding stood at $108.2 million in 2021, then rose by 11.92% to $121.1 million in 2022, then increased by 5.24% to $127.5 million in 2023, then surged by 31.61% to $167.8 million in 2024, then increased by 3.64% to $173.9 million in 2025.
  • Per Business Quant, the three most recent readings for RLAY's Shares Outstanding are $173.9 million (Q4 2025), $172.6 million (Q3 2025), and $171.7 million (Q2 2025).